IBS Issues

IBS - A Daily Challenge
Irritable Bowel Syndrome (IBS) is one of the most widespread and costly gastrointestinal disorders. Globally, the prevalence of IBS is estimated to be around 15%, with symptoms occurring in about 10-20% of the population in Western countries. The condition is characterized by symptoms such as abdominal pain, bloating, and irregular bowel movement. These symptoms can lead to a significant deterioration in the quality of life for affected individuals.
Alnozine, developed by Milmed Unico AB, is classified as a dietary supplement and adheres to the regulations set by the National Food Agency. This unique pharmabiotic product is derived from yeast cells treated with electromagnetic millimeter waves. It is designed to be part of a balanced diet and contribute to a less troubled stomach.
Alnozine (Milmed) is patent protected, patent no. PCT/SE2022/050656 "YEAST FOR THE TREATMENT OF INFLAMMATION". The patent is based on two studies, both of which are published scientific articles, see ABOUT ALNOZINE ABOUT ALNOZINE.

Customer stories

Liliane
65 years

Lotta
52 years

Susanne
58 years

Patrik
57 years

Maria
29 years

Katarina
57 years

Linda
26 years

Birgitta
67 years
Listen to Lotta and Patriks experiences with Alnozine.

Clinical Studies and Research
Alnozine™ is a food supplement that has undergone research and collaborations with leading research institutions, for example with Sapienza University. These studies have been conducted to understand more about Alnozine's effect and efficiency and that there is no toxicity in the product. It is important to note that Alnozine are intended to supplement the diet and should not be regarded as a substitute for a varied diet and healthy lifestyle.
